TABLE 6.
Treatment of metachronous cancer arising in other organ
| Total number of metachronous cancers a | Endoscopic resection | Surgery‐based therapy | Chemoradiation‐based therapy | Chemotherapy or hormonal therapy | Observation | TACE/RFA b | |
|---|---|---|---|---|---|---|---|
| Esophageal cancer | 90 | 74 | 11 | 5 | 0 | 0 | 0 |
| Gastric cancer | 16 | 12 | 4 | 0 | 0 | 0 | 0 |
| Lung cancer | 10 | 1 | 6 | 2 | 1 | 0 | 0 |
| Colorectal cancer | 5 | 1 | 3 | 0 | 0 | 1 | 0 |
| Bile‐duct cancer | 4 | 0 | 3 | 0 | 1 | 0 | 0 |
| Liver cancer | 2 | 0 | 1 | 0 | 0 | 0 | 1 |
| Duodenal cancer | 1 | 0 | 0 | 0 | 0 | 1 | 0 |
| Prostate cancer | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| Urinary tract cancer | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| Thyroid cancer | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| Total | 131 | 88 | 30 | 7 | 3 | 2 | 1 |
a
Including overlapping patients.
b
TACE: transcatheter arterial chemoembolization, RFA: radiofrequency ablation.